32 results
424B5
IFRX
InflaRx N.V.
28 Jun 24
Prospectus supplement for primary offering
4:56pm
therapeutic targets and associated methods of treatment and any other inventions that are commercially important to our business. We also rely on trade … dividends. This legislation generally targets situations in which a shareholder retains its economic interest in shares but reduces the withholding
6-K
EX-99.2
IFRX
InflaRx N.V.
5 Jun 24
InflaRx Hosts R&D Event Highlighting the Promise of INF904
5:07pm
-stage pipeline targets multiple sizable markets vilobelimab C5a Inhibitor IFX002 C5a Inhibitor INF904 Oral C5aR Inhibitor IMMUNO-DERMATOLOGY … /epidermal junction (DEJ) as targets of auto-antibody formation in Pemphigoid Disease Schmidt and Zillikens, Lancet, 2013 Role of C5a/C5aR1 in blister
6-K
EX-99.2
IFRX
InflaRx N.V.
8 May 24
Report of Foreign Private Issuer
8:43am
drug candidate that targets the C5aR receptor. C5aR, a G-protein-coupled-receptor expressed primarily by granulocytes, mediates the pathophysiological … .
INF904. We are also developing INF904, a product candidate that targets the C5aR receptor. We expect to incur additional costs by advancing
6-K
EX-99.1
IFRX
InflaRx N.V.
21 Mar 24
Corporate Presentation March 2024
5:00pm
) Page 6 Focus INF904 on Immuno-Dermatology: I&I Pipeline-in-a-Drug Potential
Page 7 Late-Stage Pipeline Targets Multiple Sizable Markets vilobelimab … Acute and chronic inflammation and other conditions Over 6,000 publications on role in numerous diseases C5a/C5aR are Validated Targets Promoting
6-K
EX-99.2
ltb 5vcje
1 Nov 23
Current report (foreign)
8:04am
6-K
EX-99.2
vfl39 tnf
10 Aug 23
Report of Foreign Private Issuer
8:00am
424B5
2ehh3uv3je74i
12 Jul 23
Prospectus supplement for primary offering
12:00am
F-3
yrt6f1ubvc86w 83g
30 Jun 23
Shelf registration (foreign)
4:06pm
6-K
EX-99.2
gk79p a5ikxkn
11 May 23
Current report (foreign)
8:00am
424B5
1vc bbjs69de
13 Apr 23
Prospectus supplement for primary offering
8:48am
424B5
shc5hb
11 Apr 23
Prospectus supplement for primary offering
4:11pm
6-K
EX-99.2
h8zw6pi0 v5
9 Nov 22
Current report (foreign)
7:52am
6-K
EX-99.3
tuvv7z1si82 ntc
9 Nov 22
Current report (foreign)
7:52am
6-K
EX-99.1
e5mey uwq94
8 Sep 22
InflaRx Announces Vilobelimab Phase III Results in Critically Ill COVID-19 Patients Published in The Lancet Respiratory Medicine
8:00am
6-K
EX-99.2
fmtrja4i2w51
5 Aug 22
Current report (foreign)
6:07am
6-K
EX-99.2
wmjmq 7pt5drrw
12 May 22
Current report (foreign)
8:30am